Pharmacological characteristics and clinical outcomes of Rimegepant (Nurtec® ODT), an oral CGRP receptor antagonist for the acute treatment and prevention of migraine

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the pharmacological features and clinical outcomes of Rimegepant in treating migraines.
Conducted clinical trials to assess the efficacy and safety of Rimegepant for acute and preventive treatment.
Evaluated pharmacokinetics including absorption and half-life in healthy adults.
Assessed drug interactions with triptans.
Rimegepant shows high affinity for CGRP receptors with no significant cardiovascular risks.
Effective for reducing migraine days when taken every other day, showing a significant decrease over one month.
Low incidence of central nervous system side effects and minimal constipation reported.

Answers are grounded in this paper and cite their sources.

Demonstrates efficacy and safety of Rimegepant in migraine treatment, suggesting a flexible therapeutic option.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Ishikawa et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share